

Table S1. Formulation and particle size of various CBD liposomes and CBD-PPD liposomes.

	Formulation	Size(nm)	PDI
CBD liposomes	SPC:chol:CBD=4:1:1	192.6 ± 2.84	0.209 ± 0.005
CBD-PPD liposomes (CP-liposomes)	SPC:PPD:CBD =4:1:1	138.8 ± 1.76	0.245 ± 0.006
PPD liposomes	SPC:PPD=4:1	113.5 ± 2.39	0.323 ± 0.026
maltose modified CBD liposomes (GMC-liposomes)	SPC:chol:CBD:Mal=4:1:1:1	145.0 ± 2.97	0.270 ± 0.010
maltose modified CBD-PPD liposomes (GMCP-liposomes)	SPC:PPD:CBD:Mal =4:1:1:1	179.3 ± 2.29	0.267 ± 0.018




Figure S1. Schematic illustration of treatment of chemotherapy to a 4T1 tumor-bearing mice.




Figure S2: The PDI value of CP-liposome (a) and GMCP-liposome (b) in various physical media at 37°C.




Figure S3: The tumor cell growth inhibition curve of free CBD, CP-liposomes, GMCP-liposomes against MCF-7 cell line (a), A549 cell line (b), C6 cell line (c), HeLa cell line (d) and HepG2 cell line (e). The tumor cell growth inhibition curve of free CBD, CP-liposomes, GMCP-liposomes, PPD liposomes and CBD-liposomes against 4T1 cell line (f).